Corporation has announced preliminary results from its analysis of its
randomized, double-blind, placebo-controlled phase III study of Provenge (APC
8015) for the treatment of hormone-resistant prostate cancer. The trial of the
cancer vaccine (D9901) involved 127 men with late-stage, metastatic,
hormone-resistant prostate cancer, 82 of whom received Provenge, three
vaccinations over a 4-week period.
The vaccine utilizes a recombinant form of prostatic acid
phosphatase (PAP), an antigen found in 95% of prostate cancers.
The results showed that men with a Gleason score of 7 or less significantly
benefited from Provenge in terms of time to disease progression.